Navigation Links
Bionovo Reports First Quarter 2008 Financial Results
Date:5/9/2008

EMERYVILLE, Calif., May 9 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) today announced results for the first quarter of 2008.

Quarter Results

The company did not report any revenue for the three months ended March 31, 2008. Revenues for the three months ended March 31, 2007 were $3,750, received from our licensing and technology transfer agreement with United Biotechnology Corporation of Taiwan. In October of 2007, we terminated the agreement following notice of material breach of the Agreement by UBC and we recognized the remaining deferred revenue of $91,250 in December 2007.

Total operating expenses for the three months ending March 31, 2008 were $4.2 million compared to $3.5 million for the same period in 2007.

The company reported a net loss for the three months ended March 31, 2008 of $3.9 million, or $0.05 per share, compared with a net loss of $3.3 million, or $0.05 per share, for the same period in 2007.

The Company ended the quarter with $29.4 million in cash, cash equivalents and short term investments, and began the quarter with $33.3 million, a difference of $3.9 million.

Company Highlights

-- Patient enrollment and dosing continues in the Phase 1 portion of the

BZL101 Phase 1/2 clinical trial for advanced metastatic breast cancer.

Presentations, papers and scientific discussions have expounded the

mechanisms of action and described the positive progress to date.

-- Bionovo presented data on two additional preclinical anti-cancer drug

candidates -- BN107 and BN108 -- at the American Association of Cancer

Research (AACR) conference in April. BN107 induces apoptosis through

the mitochondrial path
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research
2. Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness
3. Louis Drapeau Joins Bionovos Board of Directors
4. George Butler Joins Bionovos Board of Directors
5. Bionovo to Present at Bank of Montreals 2007 Focus on Healthcare Conference
6. Bionovo Announces Third Quarter 2007 Financial Results
7. Bionovo Announces the Pricing of Public Offering of Shares of Common Stock
8. Bionovo to Present at the Biotechnology Industry Organization (BIO) Investor Forum
9. Bionovo Announces Proposed Public Offering of Common Stock
10. Bionovo to Present at A.G. Edwards 2nd Annual Emerging Growth Conference 2007
11. WorldHeart Reports an Event of Default Under the Note Issued to Abiomed, Resignation of One of Its Board of Directors, and Results of Shareholder Vote at Its Annual Shareholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... In recent years, growing suspicion about ... product development and promotion has led to unprecedented levels ... by concerns about the insidious impact of commercialization of ... fines to the world’s biggest pharmas for illegal marketing ...
(Date:1/14/2014)... Bellingham, Washington, USA, and Cardiff, UK (PRWEB) January 13, ... and photonics technology development leader with more than 20 ... international society for optics and photonics . Hainsey will ... “We are delighted to have Dr. Hainsey join SPIE ...
(Date:1/14/2014)... BioMedomics, Inc. , a Point of ... and novel disease specific POC tests, announced today that it ... total of $690,000. The investment is from private investors and ... group of private investors has significant successful experience in early ...
Breaking Biology Technology:EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2BioMedomics, Inc. Closes $690K Round of Financing 2
... Coalition to Save Pure, a group of stockholders and director ... replace the current board of directors of Pure Bioscience, Inc. ... statement with the Securities and Exchange Commission. ... antibacterial, antiviral and antifungal technology. In the filing, ...
... LOS ANGELES, Dec. 22, 2011 Thanks to continued ... advocates, the Pacific Meso Center (PMC) announces the opening ... to the discovery of new treatments for malignant pleural ... by asbestos exposure. Pacific Meso Center (PMC) ...
... Life in Science," ASU Foundation Professor and Director of the Origins ... very public modern physicist, has been chosen as the 2011 Book ... Feynman is one of the most famous physicists of the ... bring science to the people, taking time to explain in simple ...
Cached Biology Technology:Coalition to Save Pure Files Proxy Documents With SEC, Urges Pure's Board to Set an Annual Meeting Date 2First Free-Standing International Mesothelioma Research Laboratory Opens in Los Angeles 2Book on Richard Feynman nets honors for Arizona State professor 2Book on Richard Feynman nets honors for Arizona State professor 3
(Date:7/9/2014)... Researchers from The Cancer Genome Atlas (TCGA) Research ... cancer-causing pathway in lung adenocarcinoma, the most common ... changes may expand the number of possible therapeutic ... greater number of patients with treatable mutations because ... already exist. , TCGA is jointly funded and ...
(Date:7/9/2014)... Ill. With over 100 diseases that can attack ... top of the most wanted list? University of Illinois ... that more research is needed on the fungus that ... with cool, damp growing conditions but Macrophomina phaseolina ... and dry drought conditions. , "As the climate continues ...
(Date:7/9/2014)... announce themselves with pain and fever but often can be ... are sneaky and hard to beat. Now, scientists have built ... tiny DNA pyramids. Published in the journal ACS Applied ... flag bacteria and kill more of them than medicine alone. ... infectious pathogens can lie in wait, undetectable in the human ...
Breaking Biology News(10 mins):Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3Climate change provides good growing conditions for charcoal rot in soybeans 2Climate change provides good growing conditions for charcoal rot in soybeans 3
... If you,re one of the millions who dread the spring ... in the May 2009 issue of the Journal of ... of American scientists have identified a previously unknown cellular switch ... important, this study also suggests that at least for some ...
... 1918 a human influenza virus known as the Spanish ... swine respiratory disease occurred concurrently. A Kansas State University ... was able to infect and replicate in pigs, but ... like monkeys, mice and ferrets where the infection has ...
... common plant toxins that affect human health and ecosystems ... new study also suggest that smoldering fires may produce ... human exposures to a minimum during controlled burns. ... helps researchers understand how they cycle through earth and ...
Cached Biology News:Just in time for spring: Scientists find the cellular on and off switch for allergies and asthma 2K-State researcher finds 1918 flu resulted in current lineage of H1N1 swine influenza viruses 2Potentially harmful chemicals found in forest fire smoke 2
Full-length cDNA clone CS0DJ013YG01 of T cells (Jurkat cell line) of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86SZ3] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
...
...
All-in-one mix, removes primers and dNTPs from PCR product for following direct sequencing...
Biology Products: